X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA IPCA LABS SHASUN PHARMA/
IPCA LABS
 
P/E (TTM) x 123.9 29.1 426.0% View Chart
P/BV x 8.5 3.5 247.4% View Chart
Dividend Yield % 0.2 0.1 171.4%  

Financials

 SHASUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
IPCA LABS
Mar-18
SHASUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs94695 13.5%   
Low Rs46400 11.4%   
Sales per share (Unadj.) Rs214.2260.2 82.3%  
Earnings per share (Unadj.) Rs5.319.0 28.1%  
Cash flow per share (Unadj.) Rs15.833.1 47.9%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %1.40.2 783.5%  
Book value per share (Unadj.) Rs53.3213.0 25.0%  
Shares outstanding (eoy) m56.62126.20 44.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.1 15.5%   
Avg P/E ratio x13.128.9 45.4%  
P/CF ratio (eoy) x4.416.6 26.7%  
Price / Book Value ratio x1.32.6 51.0%  
Dividend payout %18.75.3 355.5%   
Avg Mkt Cap Rs m3,95869,120 5.7%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m2,1647,359 29.4%   
Avg. sales/employee Rs ThNM2,477.4-  
Avg. wages/employee Rs ThNM555.2-  
Avg. net profit/employee Rs ThNM180.6-  
INCOME DATA
Net Sales Rs m12,12732,836 36.9%  
Other income Rs m229418 54.9%   
Total revenues Rs m12,35633,254 37.2%   
Gross profit Rs m1,0094,505 22.4%  
Depreciation Rs m5941,777 33.4%   
Interest Rs m415240 172.8%   
Profit before tax Rs m2302,905 7.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73511 -14.2%   
Profit after tax Rs m3022,394 12.6%  
Gross profit margin %8.313.7 60.7%  
Effective tax rate %-31.717.6 -180.0%   
Net profit margin %2.57.3 34.2%  
BALANCE SHEET DATA
Current assets Rs m6,88419,455 35.4%   
Current liabilities Rs m8,45610,076 83.9%   
Net working cap to sales %-13.028.6 -45.4%  
Current ratio x0.81.9 42.2%  
Inventory Days Days6298 63.0%  
Debtors Days Days10867 160.6%  
Net fixed assets Rs m4,97020,260 24.5%   
Share capital Rs m113252 44.9%   
"Free" reserves Rs m2,87526,633 10.8%   
Net worth Rs m3,02026,886 11.2%   
Long term debt Rs m1,8172,340 77.7%   
Total assets Rs m13,34741,173 32.4%  
Interest coverage x1.613.1 11.9%   
Debt to equity ratio x0.60.1 691.4%  
Sales to assets ratio x0.90.8 113.9%   
Return on assets %5.46.4 84.0%  
Return on equity %10.08.9 112.3%  
Return on capital %13.310.8 123.8%  
Exports to sales %46.447.6 97.3%   
Imports to sales %14.214.9 95.8%   
Exports (fob) Rs m5,62215,642 35.9%   
Imports (cif) Rs m1,7284,884 35.4%   
Fx inflow Rs m5,84315,642 37.4%   
Fx outflow Rs m2,1734,884 44.5%   
Net fx Rs m3,66910,759 34.1%   
CASH FLOW
From Operations Rs m3983,411 11.7%  
From Investments Rs m-1,635-1,354 120.8%  
From Financial Activity Rs m1,309-1,304 -100.3%  
Net Cashflow Rs m71753 9.5%  

Share Holding

Indian Promoters % 39.2 45.9 85.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 11.4 31.6%  
FIIs % 17.6 25.3 69.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.4 227.6%  
Shareholders   20,750 36,892 56.2%  
Pledged promoter(s) holding % 12.3 2.1 574.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal & Realty Stocks Drag(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.1% while the Hang Seng is down 0.5%.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS